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ABSTRACT
BACKGROUND: Fentanyl-induced cough is common but has nor been viewed as
a serious anesthetic problem. However, the cough may be explosive at times, may
require immediate intervention, and may be associated with undesirable increases in
intracranial, intraocular, and intra-abdominal pressures. Prevention of fentanyl-
induced cough in such situations is of paramount importance. Ketamine, at concen-
trations achieved with standard clinical doses, has a direct relaxant effect on airway
smooth muscle.
OBJECTIVE: This study was designed to assess the effects of ketarnine or lido-
caine on fentanyl-induced cough.
METHODS: This double-blind, randomized, placebo-controlled study was con-
ducted at the Erciyes University Medical School, Kayseri, Turkey. Consecutive adult
patients aged 18 to 65 years and classified as American Society of Anesthesiologists
physical status I or II who were undergoing elective surgery with general anesthesia
were enrolled. Patients were randomly allocated equally into 3 groups to receive lidocaine
1 mg/kg, ketamine 0.5 mg/kg, or placebo intravenously 1 minute before fentanyl
administration. Following intravenous fentanyl (1.5 pg/kg over 2 seconds) injection,
an observer, unaware of the type of medication given to the patients, recorded the
number of episodes of coughing, if any. Any episode of cough was classified as cough-
ing and graded by investigators blinded to treatment as mild (1-2 coughs), moderate
(3-4), or severe (;~5). Blood pressure, heart rate, pulse oximetry oxygen saturation
(SpOz)' and adverse effects (AEs) were recorded.
RESULTS: A total of 368 patients were approached for inclusion; 300 patients
met the inclusion criteria and were enrolled in the study. No patients in the ketamine
group had cough. The frequency of cough was significantly lower in the lidocaine
(11/100 [11 %}; P = 0.024) and ketamine (0/100; P = 0.001) groups compared with
the placebo group (23/100 [23%}). The intensity of cough was significantly lower in
the lidocaine (mild, 7/100 [7%}; moderate, 4/100 [4%}; P = 0.037) and ketamine
(0/100; P < 0.001) groups compared with the placebo group (mild, 10/100 [10%};
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moderate, 12/100 [12%J; severe, 1/100 [1%J). Severe cough (;2:5) was observed in 1 pa-
tient in the placebo group. Incidence and intensity of cough were significantly decreased
in the ketamine group compared with the lidocaine group (incidence, P = 0.001; inten-
sity, P = 0.003). There were no significant differences between groups with respect to
systolic blood pressure, diastolic blood pressure, heart rate, Sp02' and AEs.
CONCLUSION: Intravenous ketamine (0.5 mg/kg) significantly reduced the re-
flex cough induced by fentanyl compared with lidocaine and placebo, and was well toler-
ated. (CurrTher Res Clin Exp. 2010;71:289-297) © 2010 Elsevier HS Journals, Inc.
KEY WORDS: fentanyl, coughing, ketamine, lidocaine.
INTRODUCTION
Fentanyl is often used as a preinduction adjunct to anesthesia because of its quick
onset, short duration of action, intense analgesia, cardiovascular stability, and low
histamine release properties; however, reflex cough is often observed after the admin-
istration of an intravenous bolus of fentanyl. 1-5 According to reports, the incidence of
fentanyl-induced cough can reach 65%. It is usually transient and self-limiting in
patients. However, fentanyl-induced coughing may not always be brief and benign.
Tweed and Dakin6 found that an episode of explosive coughing after intravenous
fentanyl in a boy aged 7 years led to multiple conjunctival and periorbital petechiae.
Therefore, it is necessary to prevent fentanyl-induced cough in patients with some
coexisting diseases including increased intracranial pressure, open eye injury, dissect-
ing aortic aneurysm, pneumothorax, or reactive airway disease. 6,7 Fentanyl-induced
coughing may be more severe or occur at a higher incidence in patients with these
coexisting conditions.
The mechanism of fentanyl-induced cough is still unknown. Various mechanisms
proposed to explain fentanyl-induced cough are as follows: inhibition of central sym-
pathetic outflow leading to vagal predorninance.f histamine release," and deformation
of the tracheobronchial wall stimulating the irritant receptors, leading to reflex bron-
choconstriction and cough. 2,3 Various attempts have been made to reduce its incidence
during the induction of anesthesia, with varying success. Agarwal et aI,7 in a study of
200 American Society of Anesthesiologists (ASA) status I and II patients of either sex,
aged 18 to 60 years, observed a 28% incidence of cough when fentanyl (2 pg/kg IV)
was administered to the control group and reported that aerosol inhalation of salbu-
tamol (6% incidence of cough), beclomethasone (0%), or sodium chromoglycate (4%)
15 minutes prior to entering the operating room was associated with a reduced inci-
dence of cough. Horng at apo found that pretreatment with intravenous clonidine
(2 pg/kg 2 minutes before the injection of a bolus intravenous fentanyl) suppressed
the reflex cough induced by fentanyl in ASA status I and II patients, aged 18 to 80 years,
but hemodynamic changes occurred. However, because these methods can be inconve-
nient and increase cost, their clinical acceptance is somewhat Iimired.o!" There are
conflicting studies on the effect of injection time on fentanyl-induced coughing.4,1l
One study found that prolongation of the injection time reduced the incidence of
fentanyl-induced cough." A second study found that fentanyl-induced cough did not
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depend on injection speed. 11 In placebo-controlled clinical studies, it was found that
pretreatment with intravenous lidocaine reduced fentanyl-induced cough. 5,12,13 This
method seems to be effective and convenient in clinical practice, but does not com-
pletely eliminate fentanyl-induced cough.
Ketamine is a versatile drug and the R(-)-enantiomer has an effect on airway smooth-
muscle relaxation. 14 Karnei et aP5 reported that Nvmerhyl-o-asparcate (NMDA) recep-
tor antagonists are capable of modulating the cough reflex. Therefore, the present
study was conducted in an attempt to find a simple method that might effectively
attenuate fentanyl-induced cough while being convenient in a clinical setting.
PATIENTS AND METHODS
Approval was obtained from the ethics committee of the Erciyes University Medical
School, Kayseri, Turkey. Written informed consent was obtained from all patients
before they were enrolled into this prospective, double-blind, randomized, placebo-
controlled study. Consecutive adult patients aged between 18 and 65 years were cat-
egorized as being a normal healthy patient (ASA status I) or a patient with mild
systemic disease (status II).16 Patients were enrolled between October 2, 2007, and
November 5, 2008. All eligible patients who were scheduled for various elective sur-
geries under general anesthesia in the Gevher Nesibe Hospital, Kayseri, Turkey, were
enrolled into the study.
Exclusion criteria included a history of asthma, chronic cough, smoking, upper res-
piratory tract infection in the previous 2 weeks, impaired kidney or liver function,
weight exceeding 20% of ideal, medication containing angiotensin-converting enzyme
inhibitors, antidepressants, bronchodilators, and steroid or anestheric premedication.
Patients were randomized using a computer-generated random number table; the
group assignment was prepared by the enrolling anesthesiologist in sealed opaque
envelopes. The enrolling anesthesiologist was not the same as the treating anesthesi-
ologist. A total of 300 sealed envelopes containing the names of the groups (100 for
each) were prepared before initiation of the study. The envelopes were opened before
induction of anesthesia, and the drugs were prepared by an independent nurse who
was not participating in any other part of the study.
In the operating room, venous access was established on the dorsum of the non-
dominant hand, and an intravenous cannula was connected to a T-connector for drug
injection. All patients were monitored by ECG, noninvasive blood pressure measure-
ment, and pulse oximetry. Patients received lidocaine" 1 mg/kg IV in 5 mL of normal
saline, ketamine" 0.5 mg/kg IV in 5 mL of normal saline, or 5 mL of normal saline IV
alone over 5 seconds, 1 minute prior to the intravenous administration of fentanyl
(1.5 jlg/kg over 2 seconds). Any episode of cough was classified as coughing. An ob-
server, blinded to the type of medication administered to the patients, recorded the
number of episodes of coughing, if any. There were 3 observers present for all 300 pa-
tients. The severity of cough was graded as mild (1-2 coughs), moderate (3-4), or
*Trademark: Arithmal 2% (Biosel, Istanbul, Turkey).
t Trademark: Keralar (Pfizer, Isranbul, Turkey).
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severe (::::: 5), based on the nu mber of coughs within 1 mi nute following fentan yl injec-
tion . Systo lic and diastol ic blood pressure (SBP and DBP), heart rate (H R), and pul se
oximet ry oxygen saturat ion (SpO ) were recorded before the administration of each
d rug (0) and 1 minute after fentanyl in jection. All patients were given oxygen via a
face mask . The adverse effects (AEs) associated with fent anyl, ketarnine, or lidocaine,
such as apnea, truncal rigidity, nausea, hypotension, respirator depression , bradycar-
dia, or altered consciousness,17.18 were also record ed before induct ion for general an-
esthesia. General anesthesia was induced via int ravenous propofol (2 mg /kg) and
vecuronium (0.1 mg/kg).
STATISTICAL ANALYSIS
Considering the expected incidence of cough following peripherally administered
intravenous fentanyl to be 25 % , and assuming a reducti on of Q O% following an y of
th e treatments and a power of 80% , the minimum sample size required in each group
was 86. Anticipating some variability in reduction, we enro lled 100 patients in each
g roup . Patients' characterist ics were compared using I-way ANOVA. Comparison
between the groups was performed for overall inciden ce of cough and severity of
cough by X2 testing . P < 0.05 was considered stati st ically sig nificant .
RESULTS
A rotal of 368 consecut ive pat ients were approached for study inclusion ; 68 were
not included (4 5 pat ients were cur rent smokers and 23 patients were receiv ing
angiotensin-convert ing enzyme inhibitors, antidepressants, or bronchodil arors) in th e
stu dy based on the exclusion criteria. Three hundred pati ents completed the study.
There were no significant differences in the demographic data between the 3 groups,
including age , gender, weight , and ASA physical status (Table I).
No pat ients in the kerarnine group had cough (Table II ). The frequency of cough was
significantly lower in the lidocaine (11/ 100 [ll%}; P = 0.024) and ketamine (0/100;
P = 0.001) groups compared with the placebo g roup (23/100 (23%}). The mean inte n-
sity of cough was significantl y lower in the lidocaine (mild , 7/100 {7%}; moderate,
4/100 {4%}; P = 0.037) and kerarnine (0/100; P < 0.00 1) groups compared with the
placebo group (mild, 10/100 {l0%}; moderate, 12/100 {l 2%}; severe, 1/100 (l %}).
Table I. Demographic characteristics of the study populatlon.*
Variable
Age, mean (SO), y
Male/female
Weight , mean (SO), kg
ASA status 1/11
Lidocaine
(n = 100)
33.0 (9. 8)
51/49
68.8 (10 .7)
84/16
Ketamine
(n = 100)
34.1 (12.2)
55/45
70 .2 (10 .5 )
81/19
Placebo
(n = 100)
36.4 (9.8)
48/52
71.5 (1 2.5 )
82/18
ASA =American Society of Anesthesiologists.
* No signif icant between-group differenc es were observed.
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Table II. Frequency and intensity of cough induced by fentanyl. Data are number (%) of
patients (95% CI).
Lidocaine Ketamine Placebo
Severity* (n = 100) (n = 100) (n = 100)
No cough 89 (89) (0.81- 0.94) 100 (100 ) (0.97- 1.00) 77 (77) (0.68-0.85)
Mild 7 (7) (0.03- 0.14) o (O.00- 0.03)t 10 (10) (0.05-0.18)
Moderate 4 (4) (0.01- 0.10) o (O.00-0.03)t 12 (12) (0.06- 0. 20)
Severe o (0.00- 0 .03) o (0.00- 0.03) 1 (1) (0.00-0.05)
Overall incidence 11 (11) (O.06- 0.19)f o (O.OO-0.03)§1I 23 (23) (O.15-0.32)~
*Severity: No cough (0 coughs), mild (1- 2), moderate (3-4), severe ( ~ 5) .
t P = 0.003 versus lidocaine.
t P =0.024 versus placebo.
§ P = 0.001 versus placebo.
II P =0.001 versus lidocaine.
~ Inten sity of cough was significantly higher in the placebo group compared with the lidocaine (P =
0.037) and ketami ne (P < 0.001) groups.
Incidence and intensi ty of cough were sig nificantly decreased in the kerarnine gro up
compared with th e lidocaine group (incidence, P = 0.00 1; inte nsi ty, P = 0.00 3).
T he basel ine and 1 minute after fentanyl injecti on viral-sig n profiles were not sig-
nificantly different between the 3 gro ups. There were no significant differences among
gro ups for th e SBP, DBP, HR, and Sp0 2 values (Table III ).
No AEs associated with fent anyl , kerarnine, or lid ocaine were observed in any of
the pat ients th roug hout th e stu dy.
DISCUSSION
Th is study sugges ts that pretreatment with kerarnine 0.5 mg/kg IV 1 minute prior
to fent anyl adm inistra tio n was associated with attenuati ng the coughing induced by
fentanyl. This result is consistent with that from a stu dy by Yeh at al. 19 Th at study
compared the effects of low-dose kerarnine and placebo on fentanyl (1.5 Ilg/kg)-
induced coughing in 360 ASA physical status I and II pat ients (aged 18-65 years;
weight 40-80 kg) and reported that patients in the placebo g roup had a significantly
high er frequency of cough th an those in the ketamine pretreatment group (21.6% vs
7.2 %; P < 0.05). In th e present study, although a higher dose of kerarnine was used
than th e dose that Yeh at al used in their study, th e effect of ketarnine on fentan yl-
induced coughing increased with out an increase in AEs.
In th e present stu dy, coug hing occurred in 23% of patients in th e placebo g roup .
Phua at all found that fentanyl 1.5 ug/kg , administe red through a peripheral venous
line elicited cough in 28% (14/50 patients) of the pati ents. A similar incidence of
cough after fentanyl 2 Jlg/kg IV administered through th e same rout e over a period of
5 seconds was observed by Agarwal et al.7 Th ese results are not sig nificantly different
from the findings of th e present study.
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Table III. Comparison of the hemodynamic data and pulse oximetry oxygen saturation
(5p02) of the 3 groups. Data are mean (SO).
Lidocaine Ketamine Placebo
Variable (n = 100) (n = 100) (n = 100) p*
SBP, mm Hg
Baseline 133.5 (15) 130.4 (14) 134.8 (19) 0.245
One minute 120.5 (15) 120.6 (17) 122.5 (18) 0.763
DBP, mm Hg
Baseline 82.6 (90) 84.6 (10) 83.4 (11) 0.432
One minute 75.4 (12) 77.7 (12) 75.1 (12) 0.275
HR, beats/min
Baseline 87.8 (13) 84.7 (15) 85.2 (14) 0.309
One minute 84.7 (12) 86.8 (12) 82.6 (12) 0.087
Sp02' %
Baseline 98.7 (1.1) 98.6 (1.2) 98.6 (1.2) 0.635
One minute 98.7 (1.1) 98.8 (1.1) 98.8 (1.1) 0.598
SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate.
*No statistically significant differences were observed between groups.
The exact mechanism of fentanyl-induced cough is still unclear. Some studies re-
port that fentanyl inhibits central sympathetic outflow and therefore activares the
vagus nerve, which induces cough and reflex bronchoconsrricrion.s-e" However, the
involvement of a vagal-dependent pathway was not favored in previous studies be-
cause atropine, an antimuscarinic agent, failed ro suppress cough.1,2 Another likely
mechanism is pulmonary chemoreflex, which is mediated by either irritant receptors
(rapidly adapting receptors) or by vagal C fiber receptors that are in proximity to
pulmonary vessels (juxtacapillary receptorsr.I-" However, experimental studies have
found that juxtacapillary-recepror stimulation did not induce cough, although it did
mediate pulmonary chemoreflexes.V Histamine release in humans from lung mast cells
is a possible mechanism of fentanyl-induced cough, though this appears very unlikely as
fentanyl rarely causes histamine release.? Suppression of cough with inhaled betametha-
sone (as it is known to reduce bronchial hyperirritability, mucosal edema, and also to
suppress the inflammatory response to trigger stimuli) supports the trigger stimulus
and bronchial hyperirritability theory.? In addition to this, terbutaline and salbutamol
(a selective p2-adrenergic bronchodilator) inhalation and effective suppression of cough
support the concept of bronchoconsrriction. Constriction of the tracheal smooth mus-
cles and the possible stimulation of irritant receptors after deformation of the tracheo-
bronchial wall triggering the cough are other plausible explanations, 3,9
Although intravenous kerarnine prevented fentanyl-induced cough in the present
study, the actual mechanism is unknown. The presence of NMDA receptors has been
reported in the larynx, lung, and airways, and activation of these receprors can trigger
airway constriction.f' Therefore, the direct bronchodilation effect ofketamine may be
attributed to its NMDA-receptor antagonism. However, Sato et a124 reported that
ketarnine relaxes the tracheal smooth muscle contracted by histamine through a
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mechanism independent of NMDA receptors. In another study, Sato et ails investi-
gated whether the relaxant effect of ketamine is dependent on any of the epithelium-
derived relaxing factors and concluded that ketamine relaxes the airway smooth
muscle by an epithelium-independent mechanism. However, Durieux/f reported that
ketamine inhibited muscarinic acetylcholine receptor function. Postsynaptic acetyl-
choline receptors may have a major role in distal airway tone, and ketamine possibly
acts as a bronchodilator in this way.
Gateau et al27 found that ketamine antagonizes bronchocontraction via histamine,
acetylcholine, barium chloride, and potassium chloride. The investigators also theo-
rized that, because ketamine exerts a nonspecific antagonism to multiple bronchocon-
strictors, there might be inhibition of a common pathway leading to bronchorelax-
ation. Abdalla er al28 hypothesized that ketamine inhibits the transmembrane influx
of calcium (Ca2+) , because ketarnine was able to bronchodilate airway smooth muscle
contracted with potassium chloride, which is known to change membrane potential and
allow a greater influx of Ca2+ .27 However, Yeh et aP9 speculated that keramine counter-
acts the action of fentanyl by preserving the sympathetic-parasympathetic balance,
which might affect the incidence of cough. These data have suggested that ketamine
acts as a bronchodilator by a variety of mechanisms.
Although the bronchodilation effect of lidocaine has been quesrioned.i? intrave-
nous lidocaine administration has been found to suppress both mechanically and
chemically induced airway reflexes, including the cough reflex. 30,3 ) The mechanisms
by which lidocaine suppresses cough are not known, but it has been proposed that
depression of brain-stem functions by lidocaine may be responsible for cough suppres-
sion. An alternative mechanism is that lidocaine may act by anesthetizing peripheral
cough receptors in the trachea and hypopharynx. 32
CONCLUSIONS
Intravenously administered ketamine 0.5 mg/kg and lidocaine 1 mg/kg were associ-
ated with significantly reduced incidence of fentanyl-induced cough compared with
placebo in these patients undergoing elective surgery with general anesthesia. The
reduction was significantly greater in the ketamine group compared with the lido-
caine group. Both treatments were well tolerated.
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